Work

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.5010

Authors: Michael J. Morris, Jeffrey Y.C. Wong, Luke Nordquist, Russell Zelig Szmulewitz, Neeraj Agarwal, Edward F. Attiyeh, Steven I Max, Chaitanya R. Divgi, Daniel Patricia, Yu Cao, Xiang Li, Alex Yu, Karen Urtishak, Josh David Lauring, Oliver Sartor

Institutions: Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, University of Chicago, Huntsman Cancer Institute, Mayo Clinic

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Research and Development

OpenAlex ID: W4399381283

Cites:

Cited by: 14

Related to: 10